The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts say.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant access to gene-editing therapy on the NHS. View on euronews

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain patients with severe sickle cell disease. Here patients have reacted to the news:

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by approval for transfusion-dependent beta-thalassemia (TDT) in January 2024. NHS England reached an earlier reimbursement agreement for Casgevy in TDT in August 2024.

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off treatment costs more than £1million per patient but may essentially

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell disease.

A groundbreaking £1.65million gene therapy treatment offering hope for sickle cell disease patients has been approved for use on the NHS in England. The one-time treatment, called Casgevy (exa-cel), has shown remarkable success in clinical trials,

NHS Karla Sofia Gascón apologizes for old tweets, says she is 'deeply sorry to those I have caused pain' Everything we know about China's new 6th gen fighter jet... AstraZeneca cancels £450m investmen